Drug makers and regulators take aim at Omicron.
Deals will come into even greater focus after the failure of ligelizumab, one of the group’s brightest pipeline hopes.
Followers of novel immuno-oncology mechanisms will note Astrazeneca as a new player in Tigit and Tim3.
But investors will need more convincing; and others are more advanced, with Arrowhead and Inhibrx ones to watch.
Data are due in the fourth quarter for Aldeyra, Aeglea and Radius, among other small developers.
The anti-Tigit MAb domvanalimab will generate key clinical results any day; will they be good enough for Gilead to opt in?
A small molecule for alpha-1 antitrypsin deficiency faces a key clinical test, and its chances of success aren’t good.